Introduction
The evolution of peptide research over the past century reflects broader changes in biomedical science — from serendipitous discovery to rational design, from isolated compound characterization to systems biology understanding, and from simple hormone replacement to precision molecular targeting. Tracing this evolution illuminates where current research peptides fit in the historical arc and where the field is heading.
The First Wave: Endocrine Peptide Hormones (1920s-1960s)
Modern peptide research began with the isolation of endocrine hormones — insulin, glucagon, ACTH, vasopressin, oxytocin — from animal glands. These were identified by their physiological effects in bioassays before their structures were known. Insulin’s isolation in 1921 was the founding moment. The subsequent determination of insulin’s amino acid sequence by Sanger in 1955 and oxytocin’s chemical synthesis by du Vigneaud in 1953 established the structural-biological activity connection that frames all modern peptide pharmacology.
The Second Wave: Neuroendocrine Discovery (1960s-1980s)
The characterization of hypothalamic regulatory peptides — TRH, GnRH, somatostatin, GHRH, CRH — by Guillemin, Schally, and their colleagues opened the neuroendocrine era. These discoveries revealed that the brain controls the pituitary and peripheral endocrine glands through peptide signals, and that these signals could be pharmacologically manipulated. The peptide drug programs that followed — GnRH agonists for hormone-sensitive cancers, somatostatin analogues for acromegaly — demonstrated the therapeutic potential of neuroendocrine peptide pharmacology.
The Third Wave: Synthetic GHRP and Secretagogue Research (1980s-2000s)
The discovery that synthetic peptides and small molecules could stimulate GH release through a then-unrecognized receptor — later identified as the ghrelin receptor — opened the growth hormone secretagogue field. GHRP-6, GHRP-2, Ipamorelin, and Hexarelin were developed during this period. The subsequent identification of ghrelin as the endogenous GHS-R1a ligand (1999) validated the pharmacological approach and connected it to endogenous hunger biology. This period also saw the development of many of the research peptides most widely used today.
The Fourth Wave: Genomics and Rational Design (2000s-2020s)
Structural genomics, combinatorial chemistry, and computational modeling transformed peptide discovery from largely empirical to increasingly rational. Researchers could now identify peptide sequences through genome mining, model receptor binding in silico, and systematically optimize sequences through structure-activity relationship studies guided by structural data. This period produced the GLP-1 receptor agonist series (Exenatide, Liraglutide, Semaglutide, Tirzepatide) — the most commercially successful peptide drug program in history — through rational modification of natural GLP-1 sequence and systematic pharmacokinetic optimization.
The Fifth Wave: Mitochondrial and Epigenetic Peptide Biology (2015-present)
The discovery of MOTS-c (2015) and the expansion of the mitochondria-derived peptide field opened an entirely new chapter in peptide biology. The recognition that the mitochondrial genome encodes signaling peptides, that these peptides decline with age, and that they communicate between mitochondria and the nucleus — and between organs through the circulation — adds a new layer of complexity to peptide research that is only beginning to be characterized.
Toward Precision Peptide Medicine
Current research directions point toward greater receptor subtype selectivity (biased agonism, subtype-selective compounds), oral bioavailability expansion, tissue-targeted delivery, and combination approaches that engage multiple complementary pathways simultaneously. Tirzepatide’s dual agonism and Retatrutide’s triple agonism illustrate the combinatorial approach. Oral semaglutide validates the oral delivery frontier. The integration of peptide research with CRISPR, proteomics, and AI-assisted design points toward an era of increasingly precise and personalized peptide medicine.
Conclusion
Peptide research has evolved from empirical endocrine hormone isolation through rational neuroendocrine pharmacology to genomics-enabled precision design and now to mitochondrial peptide biology. Each wave built on its predecessors while opening new research frontiers. The compounds available in today’s research peptide market reflect this full evolutionary arc — from historically validated endocrine peptides to cutting-edge mitochondrial signaling molecules.